Angela Hammond
Psychiatric/Mental Health · Memphis, TNNPI 1326046707
Payments from drug & device makers
Across 812 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Supernus Pharmaceuticals, Inc.$920
- plus $5K from 19 others
What the payments were for
- Food & beverage$16,13399%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 172 | $2,898 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 102 | $2,355 |
| Alkermes, Inc. | 66 | $2,070 |
| Otsuka America Pharmaceutical, Inc. | 106 | $1,748 |
| Vanda Pharmaceuticals Inc. | 76 | $1,225 |
| Supernus Pharmaceuticals, Inc. | 29 | $920 |
| Neurocrine Biosciences, Inc. | 36 | $808 |
| Lundbeck LLC | 38 | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $527 |
| Axsome Therapeutics, Inc. | 26 | $523 |
| Teva Pharmaceuticals USA, Inc. | 17 | $464 |
| Johnson & Johnson | 20 | $387 |
| Bausch Health US, LLC | 14 | $271 |
| Merck | 17 | $270 |
| Ironshore Pharmaceuticals Inc. | 15 | $233 |
| Indivior Inc. | 12 | $191 |
| Tris Pharma Inc | 9 | $165 |
| E.r. Squibb & Sons, L.L.C. | 2 | $153 |
| Sunovion Pharmaceuticals Inc. | 7 | $132 |
| Collegium Pharmaceutical, Inc. | 6 | $96 |
| Acadia Pharmaceuticals Inc | 3 | $55 |
| Corium, LLC | 3 | $38 |
| Olympus America Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,297 in reported general payments places this provider in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 49 | $282,167 |
| FanaptIloperidone | 81 | $189,884 |
| CaplytaLumateperone Tosylate | 61 | $106,209 |
| Abilify MaintenaAripiprazole | 21 | $51,762 |
| RexultiBrexpiprazole | 36 | $51,168 |
| TrintellixVortioxetine Hydrobromide | 43 | $40,642 |
| Invega SustennaPaliperidone Palmitate | 11 | $38,188 |
| FetzimaLevomilnacipran Hcl | 34 | $32,764 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $32,502 |
| VraylarCariprazine Hcl | 20 | $29,378 |
| Chlorpromazine Hcl | 45 | $18,266 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $14,610 |
| Asenapine Maleate | 31 | $13,928 |
| Paliperidone ErPaliperidone | 74 | $13,312 |
| Divalproex Sodium ErDivalproex Sodium | 185 | $11,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $464 | $282,16749 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,225 | $189,88481 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $2,355 | $106,20961 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,748 | $102,93057 claims |
| AbbVieFetzima, Vraylar | $2,898 | $62,14354 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $527 | $46,96759 claims |
| Johnson & JohnsonInvega Sustenna | $387 | $38,18811 claims |
| Alkermes, Inc.Lybalvi | $2,070 | $32,50216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Other psychiatric/mental health in Memphis
- Mary AllenMemphis$422K
- Sarah VogelfangerMemphis$94K
- Michael HobbsMemphis$23K
- Kristen LockeMemphis$9K
- Latasha GarrettMemphis$8K
- Lisa WilliamsMemphis$8K
- Kristin FitchpatricMemphis$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.